Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307763 | 0.85 | ALDH1A1 (0.38) | TP53LMNAALDH1A1TSHRPOLB | |
| SCHEMBL307653 | 0.83 | PARP1 (0.36) | BRD4TP53GBA1POLB | |
| SCHEMBL1590183 | 0.83 | GAA (0.49) | AURKARPS6KB1BRD4TP53LMNA | |
| SCHEMBL17690513 | 0.82 | BRD4 (0.37) | BRD4TP53LMNAALDH1A1POLB | |
| SCHEMBL1590531 | 0.76 | PARP1 (0.55) | BRD4ALDH1A1GBA1TSHRPOLB | |
| SCHEMBL27776457 | 0.75 | GLA (0.42) | TP53LMNAALDH1A1TSHRPOLB | |
| SCHEMBL27776459 | 0.74 | LMNA (0.41) | TP53LMNAALDH1A1TSHRPOLB | |
| SCHEMBL12702881 | 0.71 | GAA (0.47) | BRD4TP53LMNAALDH1A1POLB | |
| SCHEMBL17690514 | 0.70 | P2RX7 (0.60) | — | |
| SCHEMBL10255904 | 0.68 | LMNA (0.43) | AURKARPS6KB1LMNAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2124562-B1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | SECOND GENOME INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-8093265-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2124562-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080287415-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2008-11-20 | — | — | US | disclosed |
| WO-2008112205-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287415-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | AURKA 4017/4885RPS6KB1 753/4885BRD4 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.